Category1 Category2 Category3

Under the terms of the agreement, Woden has agreed to acquire the ACCUM Therapeutics shares for a consideration of CAD4.5 million (US$3.6 million) paid by the issuance of 45,000,000 common shares post-consolidation at a deemed value of approximately CAD0.1 per share (US$0.08). 

ID:5P58-M8X1-JD8N-R22G_1